You also can search for our most recent work on chimeric antigen receptor T-cell (CAR T) technologies using our tags here, or via our general search engine here.
NIH CRADAs involving antigen receptor technologies. See this sheet.
CAR patent litigation
CAR IP assets
Some KEI Blogs
2018
- KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite, February 27, 2018.
- KEI asks FTC to block Celgene Acquisition of Juno Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma. February 16, 2018.
- 2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology. January 5, 2018.
- EB142: KEI statement on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. January 24, 2018
2017
- National Institutes of Health proposed exclusive license for kidney cancer patents to company without its own phone number
- Workshop: Patents, the Public Interest and Two New Medical Technologies: CRISPR and CAR T
- KEI statement regarding Gilead’s Acquisition of Kite Pharma
- KEI finds University of Pennsylvania failed to disclose government rights in five CAR T patents
- Federal funding to organizations for projects related to chimeric antigen receptors
- Kymriah, the Novartis $475,000 CAR T treatment, received 50 percent Orphan Drug tax credit on trials
- All 12 Zhang/Broad Institute CRISPR patents declare US funding and rights in inventions
2016
- Front page New York Times story explores Kite Pharma’s profitable relationship with NIH regarding expensive cancer drug
- Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute
- 2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment
- Kite Pharma Uses CRADAs to Conduct Important Clinical Research on New Cancer Treatments
- 2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc.
- 2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer